Wall Street brokerages expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to announce ($0.50) earnings per share for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.53). Syros Pharmaceuticals reported earnings of ($0.58) per share during the same quarter last year, which would indicate a positive year over year growth rate of 13.8%. The firm is expected to announce its next quarterly earnings report on Monday, March 11th.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($1.87) per share for the current year, with EPS estimates ranging from ($1.90) to ($1.85). For the next year, analysts expect that the firm will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.11) to ($1.80). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, November 1st. The company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.02). The company had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.72 million.

A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 17th. JMP Securities set a $33.00 price objective on shares of Syros Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 1st. BidaskClub raised shares of Syros Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday. HC Wainwright reissued a “hold” rating and issued a $10.00 price objective on shares of Syros Pharmaceuticals in a research report on Wednesday, August 8th. Finally, Oppenheimer set a $26.00 price objective on shares of Syros Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 1st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $19.00.

Syros Pharmaceuticals stock opened at $7.36 on Wednesday. Syros Pharmaceuticals has a 1-year low of $6.25 and a 1-year high of $15.88.

A number of hedge funds have recently modified their holdings of the business. FMR LLC grew its stake in Syros Pharmaceuticals by 3.3% in the 3rd quarter. FMR LLC now owns 5,048,158 shares of the company’s stock worth $60,124,000 after acquiring an additional 161,410 shares in the last quarter. ARK Investment Management LLC grew its stake in Syros Pharmaceuticals by 23.5% in the 3rd quarter. ARK Investment Management LLC now owns 2,221,870 shares of the company’s stock worth $26,462,000 after acquiring an additional 422,317 shares in the last quarter. BlackRock Inc. grew its stake in Syros Pharmaceuticals by 1.9% in the 3rd quarter. BlackRock Inc. now owns 1,613,668 shares of the company’s stock worth $19,219,000 after acquiring an additional 30,037 shares in the last quarter. Millennium Management LLC grew its stake in Syros Pharmaceuticals by 129.3% in the 2nd quarter. Millennium Management LLC now owns 375,466 shares of the company’s stock worth $3,834,000 after acquiring an additional 211,696 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Syros Pharmaceuticals by 2.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 369,959 shares of the company’s stock worth $4,406,000 after acquiring an additional 8,286 shares in the last quarter. Institutional investors and hedge funds own 60.74% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

See Also: What is Cost of Debt?

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.